Many studies suggest that SIRT6 expression has been reduced in many human tumors, including colorectal, pancreatic, ovarian, glioma, hepatocellular, and lung cancers, which is associated with poor clinical outcomes 10-15; Consistently, depletion of SIRT6 results in tumor formation and maintenance, indicating that SIRT6 acts as a tumor suppressor 10. Here, SIRT6 is linked to lung cancer.